ロード中...
Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes
BACKGROUND: Dysferlinopathies are a group of muscle disorders causing muscle weakness and absence or low levels of dysferlin, a type-II transmembrane protein and the causative gene of these dystrophies. Dysferlin is implicated in vesicle fusion, trafficking, and membrane repair. Muscle biopsy of pat...
保存先:
| 出版年: | BMC Musculoskelet Disord |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7697384/ https://ncbi.nlm.nih.gov/pubmed/33246442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12891-020-03756-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|